Both disodium cromoglycate (DSCG) and 2,4,6-trinitrobenzenesulfonic acid solution (TNBS) were bought from Sigma-Aldrich (St.
Hyland, "Disodium cromoglycate reverses colonic visceral hypersensitivity and influences colonic ion transport in a stress-sensitive rat strain," PLoS ONE, vol.
2 mL of disodium cromoglycate (DSCG) was set to 2 kinds of nebulizers and the nebulizers were allowed to continue for 3 minutes, 20 puffs (1 mg/a puff) for MDI, and a capsular (20 mg) form DP has emitted.
All of disodium cromoglycates (DSCG) trapped on to the GF/A filters were assayed by the HPLC (SHIMADZU LC-10ADVP (Shimadzu Corp., Tokyo Japan)) under the following conditions.
Acteoside and 1-O-caffeoyl glycoside (25 mg/kg) significantly (P < 0.05) inhibited sRaw by 32.14 and 26.79% in IAR, and by 55.88% and 52.94% in LAR, respectively, whereas caffeic acid (25 mg/kg) inhibited sRaw by 30.36% in IAR and 44.12% in LAR, compared to control, but with less effective than dexamethasone, disodium cromoglycate, and salbutamol, respectively.
In addition, prophylactic treatment with drugs such as disodium cromoglycate and glucocorticoids inhibit both the IAR and the LAR, while treatment with a [[beta].sub.2]-selective adrenoceptor agonist such as salbutamol inhibits IAR, but not LAR(Cockcroft and Murdock, 1987; Aryan and John, 1999).
Caffeic acid, ovalbumin (Type V), epiprinhydrinate, dexamethasone, salbutamol, disodium cromoglycate, and Wright's stain were purchased from Sigma Chemical Co.
Furthermore, dex-amethasone (5 mg/kg), disodium cromoglycate (10 mg/kg), and slabutamol (5 mg/kg) significantly (P < 0.05) inhibited sRaw by 37.50, 30.21 and 36.07% in IAR, and by 55.88, 52.94 and 38.24% in LAR as compared with that of control, respectively.
These results confirm the efficacy and safety profile established for salmeterol in previous short-term ([is less than or equal to] 12 weeks) studies, which compared salmeterol with albuterol, theophylline, terbutaline, disodium cromoglycate, and higher dose inhaled corticosteroids.[9,11-13,18-21] These data also confirm the experience from clinical trials that demonstrated the efficacy and safety of salmeterol therapy for periods of up to 1 year.[10,22] Therefore, maintenance therapy with salmeterol can improve pulmonary function and asthma symptoms without compromising safety, even when patients reduce their use of other nonsteroidal asthma medications.
Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma.